|
|
???tair.name??? >
???browser.page.title.author???
|
"lee kh"???jsp.browse.items-by-author.description???
Showing items 1-25 of 106 (5 Page(s) Totally)
1 2 3 4 5 > >>
View [10|25|50] records per page
| 國家衛生研究院 |
2023-12-03 |
Advantages of retrograde intrarenal incision versus laparoscopic surgery in management of pararenal cysts: A single-center experience
|
Tseng, WH;Hsieh, CC;Huang, SK;Liu, CL;Lee, KH;Hsieh, KL;Chen, ZH;Chiu, AW;Li, CF;Shiue, YL |
| 國家衛生研究院 |
2023-03-10 |
Prediction of the risk of developing end-stage renal diseases in newly diagnosed type 2 diabetes mellitus using artificial intelligence algorithms
|
Ou, SM;Tsai, MT;Lee, KH;Tseng, WC;Yang, CY;Chen, TH;Bin, PJ;Chen, TJ;Lin, YP;Sheu, WHH;Chu, YC;Tarng, DC |
| 國家衛生研究院 |
2021-10-04 |
Discovery of BPR1R024, an orally active and selective CSF1R inhibitor that exhibits antitumor and immunomodulatory activity in a murine colon tumor model
|
Lee, KH;Yen, WC;Lin, WH;Wang, PC;Lai, YL;Su, YC;Chang, CY;Wu, CS;Huang, YC;Yang, CM;Chou, LH;Yeh, TK;Chen, CT;Shih, C;Hsieh, HP |
| 國家衛生研究院 |
2020-10-24 |
Puralpha regulates the induction of Znf179 transcription during neuronal differentiation
|
Kuo, CJ;Lee, KH;Huang, CC;Wang, IF;Hsieh, CCJ;Lin, HC;Lee, YC |
| 國家衛生研究院 |
2020-01 |
Liposomal irinotecan + 5-FU/LV in metastatic pancreatic cancer: Subgroup analyses of patient, tumor, and previous treatment characteristics in the pivotal NAPOLI-1 trial
|
Macarulla Mercade, T;Chen, LT;Li, CP;Siveke, JT;Cunningham, D;Bodoky, G;Blanc, JF;Lee, KH;Dean, A;Belanger, B;Wang-Gillam, A |
| 國家衛生研究院 |
2019-12-01 |
Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study
|
Bang, YJ;Li, CP;Lee, KH;Chiu, CF;Park, JO;Shan, YS;Kim, JS;Chen, JS;Shim, HJ;Rau, KM;Choi, HJ;Oh, DY;Belanger, B;Chen, LT |
| 國家衛生研究院 |
2018-11-07 |
Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial
|
Chen, LT;Siveke, JT;Wang-Gillam, A;Li, CP;Bodoky, G;Dean, AP;Shan, YS;Jameson, GS;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Chiu, CF;Schwartsmann, G;Braiteh, FS;Mamlouk, K;Belanger, B;de Jong, FA;Hubner, RA |
| 國家衛生研究院 |
2018-11 |
Liposomal irinotecan (nal-IRI) plus 5-FU/LV in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) progressing on gemcitabine-based treatment: Further subgroup analyses of the pivotal NAPOLI-1 study
|
Chen, LT;Mercade, TM;Lee, KH;Lakatos, G;Wang-Gillam, A;Mirakhur, B;de Jong, F |
| 國家衛生研究院 |
2018-10 |
NAPOLI-1 phase III trial outcomes by prior surgery, and disease stage, in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)
|
Mercade, TM;Bodoky, G;Siveke, J;Lee, KH;Chen, J;Mirakhur, B;Dean, A;Chen, LT;de Jong, F |
| 國家衛生研究院 |
2018-09-12 |
Norepinephrine administration is associated with higher mortality in dialysis requiring acute kidney injury patients with septic shock
|
Chen, YY;Wu, VC;Huang, WC;Yeh, YC;Wu, MS;Huang, CC;Wu, KD;Fang, JT;Wu, CJ;Wu, VC;Lai, TS;Lin, YF;Tsai, IJ;Lai, CF;Huang, TM;Chu, TS;Chen, YM;Chang, YH;Yeh, YC;Lai, CH;Tseng, LJ;Wu, KD;Wang, JJ;Chen, CY;Shiao, CC;Wang, WJ;Lin, JH;Wu, CH;Wu, CJ;Lu, KC;Kan, WC;Huang, CC;Chou, CY;Yang, YF;Tsai, JP;Hu, FC;Lee, CT;Chen, JB;Lee, CH;Lee, WC;Li, LC;Chen, TC;Lin, HYH;Chen, YC;Lee, CC;Sun, CY;Pan, HC;Chang, MY;Jenq, CC;Lin, CY;Chang, CH;Tsai, TY;Chen, CM;Lin, ET;Wu, CJ;Lin, CJ;Wu, PC;Kuo, FC;Weng, CJ;Chen, LK;Lin, SL;Yang, WS;Hsu, WD;Leu, JG;Chang, JT;Liou, HH;Hsu, KH;Wu, MJ;Huang, CT;You, ZH;Chang, CF;Chen, TW;Chen, HH;Chang, FC;Lin, YC;Wu, MS;Kao, CC;Hung, SC;Kuo, KL;Wu, CH;Tarng, DC;Chen, JY;Yang, CY;Lee, KH;Ko, SW;The NSARF and CAKS Group |
| 臺大學術典藏 |
2018-09-10T07:34:16Z |
Temperature dependence of photoluminescence on molecular-beam-epitaxy grown Ga2O3 (Gd2O3)/GaAs
|
Tu, LW; Lee, YC; Lee, KH; Lai, CM; Lo, I; Hsieh, KY; Hong, M; MINGHWEI HONG |
| 臺大學術典藏 |
2018-09-10T07:34:09Z |
STRUCTURAL, MECHANICAL, THERMODYNAMIC, AND OPTICAL PROPERTIES OF CONDENSED MATTER-Temperature dependence of photoluminescence on molecular-beam-epitaxy grown Ga2O3 (Gd2O3)/GaAs
|
Tu, LW; Lee, YC; Lee, KH; Lai, CM; Lo, I; Hsieh, KY; Hong, M; MINGHWEI HONG |
| 國家衛生研究院 |
2018-02 |
Subgroup analysis by baseline (BL) weight-associated parameters: A phase III study of liposomal irinotecan (nal-IRI)+/--5fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with g
|
Macarulla, TM;Hubner, R;Blanc, JF;Wang-Gillam, A;Li, CP;Bodoky, G;Dean, AP;Yanshen, S;Jameson, GS;Lee, KH;Chiu, CF;Schwartsmann, G;Braiteh, FS;Cunningham, D;Chen, LT;Von Hoff, DD;Mamlouk, KK;de Jong, FA;Siveke, JT |
| 國家衛生研究院 |
2017-11 |
Subgroup analysis by prior non-liposomal irinotecan therapy in NAPOLI-1: A phase 3 study of nal-IRI65-fluorouracil/leucovorin in patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapy
|
Blanc, JF;Hubner, R;Li, CP;Wang-Gillam, A;Bodoky, G;Dean, A;Shan, YS;Jameson, G;Mercade, TM;Lee, KH;Cunningham, D;Chiu, CF;Schwartsmann, G;Braiteh, F;von Hoff, D;Chen, LT;Mamlouk, K;de Jong, F;Siveke, J |
| 國家衛生研究院 |
2017-09 |
Prognostic value of baseline neutrophil-to-lymphocyte ratio for predicting clinical outcome in metastatic pancreatic ductal adenocarcinoma (mPDAC) patients treated with liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV alon
|
Hubner, RA;Chen, LT;Li, CP;Bodoky, G;Dean, A;Lee, KH;Cunningham, D;Siveke, JT;Braiteh, FS;de Jong, FA;Belanger, B;Walls, R;Mody, PD;von Hoff, DD;Wang-Gillam, A |
| 國家衛生研究院 |
2017-05 |
Association of warfarin with congestive heart failure and peripheral artery occlusive disease in hemodialysis patients with atrial fibrillation
|
Lee, KH;Li, SY;Liu, JS;Huang, CT;Chen, YY;Lin, YP;Hsu, CC;Tarng, DC |
| 國家衛生研究院 |
2017-05 |
The prognostic value of baseline neutrophilto-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) for predicting clinical outcome in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan (nal-IRI; MM
|
Wang-Gillam, A;Chen, LT;Li, CP;Bodoky, G;Dean, A;Lee, KH;Cunningham, D;Hubner, R;Braiteh, FS;Pipas, JM;Belanger, B;de Jong, FA;Mody, PD;Von Hoff, DD;Siveke, JT |
| 國家衛生研究院 |
2017-04 |
One-pot tandem oxidative dearomatization/ 4+3 cycloaddition: Masked o-benzoquinone with diaza-oxyallyl cation
|
Lee, KH;Hsieh, HP |
| 國家衛生研究院 |
2017-02 |
Characteristics of long-term survivors in a randomized phase III trial (NAPOLI-1) of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan (nal-IRI; MM-398)+5-FU/LV
|
Wang-Gillam, A;Li, CP;Bodoky, G;Dean, A;Lee, KH;Cunningham, D;Hubner, R;Siveke, JT;Braiteh, FS;Pipas, JM;Belanger, B;de Jong, F;Mody, PD;Chen, LT;Von Hoff, DD |
| 國家衛生研究院 |
2016-12 |
Efficacy and safety of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02, BAX-2398) in patients with metastatic pancreatic cancer in Asia: A subgroup analysis of the phase 3 NAPOLI-1 Study
|
Chen, LT;Li, CP;Chiu, CF;Shan, YS;Park, JO;Chen, JS;Kim, JS;Rau, KM;de Jong, F;Pipas, M;Belanger, B;Wang, E;Lee, KH;Bang, YJ |
| 國家衛生研究院 |
2016-10 |
Final results of NAPOLI-1: A phase 3 study of nal-IRI (MM-398) +/- 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
|
Chen, LT;Wang-Gillam, A;Li, CP;Bodoky, G;Dean, A;Shan, YS;Jameson, GS;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Hubner, R;Chiu, CF;Schwartsmann, G;Braiteh, F;Belanger, B;Bayever, E;de Jong, F;von Hoff, DD;Siveke, JT |
| 國家衛生研究院 |
2016-10 |
Time course of selected treatment emergent adverse events (TEAEs) in NAPOLI-1: A phase 3 study of nal-IRI (MM-398) +/- 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based ther
|
Hubner, RA;Chen, LT;Siveke, JT;Li, CP;Bodoky, G;Dean, A;Shan, YS;Jameson, GS;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Chiu, CF;Schwartsmann, G;Braiteh, F;Mamlouk, K;Belanger, B;de Jong, F;von Hoff, DD;Wang-Gillam, A |
| 國家衛生研究院 |
2016-05 |
Updated overall survival (OS) analysis of NAPOLI-1: Phase 3 study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine
|
Wang-Gillam, A;Li, CP;Bodoky, G;Dean, A;Shan, YS;Jameson, GS;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Hubner, R;Chiu, CF;Schwartsmann, G;Siveke, JT;Braiteh, FS;Moyo, VM;Belanger, B;Bayever, E;Von Hoff, DD;Chen, LT |
| 國家衛生研究院 |
2016-02 |
Kidney disease progression in patients of upper tract urothelial carcinoma following unilateral radical nephroureterectomy
|
Lee, KH;Chen, YT;Chung, HJ;Liu, JS;Hsu, CC;Tarng, DC |
| 國家衛生研究院 |
2016-02 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): A global, randomised, open-label, phase 3 trial
|
Wang-Gillam, A;Li, CP;Bodoky, G;Dean, A;Shan, YS;Jameson, G;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Hubner, RA;Chiu, CF;Schwartsmann, G;Siveke, JT;Braiteh, F;Moyo, V;Belanger, B;Dhindsa, N;Bayever, E;Von Hoff, DD;Chen, LT;the NAPOLI-1 Study Group. |
Showing items 1-25 of 106 (5 Page(s) Totally)
1 2 3 4 5 > >>
View [10|25|50] records per page
|
